Dec 20 (Reuters) - Teva Pharmaceuticals (TEVA.TA), opens new tab failed to convince a U.S. appeals court on Friday to reverse a decision that would remove patents related to its ProAir HFA inhaler ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback